A pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same
WO2021075926A1
Pharmaceutical composition comprising proton pump inhibitor and antacid
WO2021066600A1
Glucagon, composition comprising glp-1 receptor and gip receptor dual agonist and therapeutic use thereof
WO2021066443A1
Pharmaceutical composition for treating acute myeloid leukemia containing flt3 inhibitor and mdm2 inhibitor
KR20210002054A
Aminocyanopyridine derivatives and its use
KR20210002055A
Therapeutic use of Trigonal glucagon/GLP-1/GIP receptor agonist or a conjugate thereof for liver disease
WO2020262998A1
Novel quinazoline derivative having anti-tumor activity and pharmaceutical composition comprising same
WO2020262974A1
Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
KR20210002012A
Novel quinazoline derivatives with anti-tumor activity and pharmaceutical composition comprising the same
WO2020214013A1
Therapeutic use, for hyperlipideamia, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof
WO2020214012A1
Preventive or therapeutic pharmaceutical composition for hyperlipidemia comprising triple agonist acting on all of glucagon, glp-1 and gip receptors, or conjugate thereof, and preventive or therapeutic method
WO2020204609A1
Pharmaceutical composition comprising esomeprazole or pharmaceutically acceptable salt thereof and having double-release profile
WO2020171646A1
Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
KR20200102949A
A pharmaceutical composition comprising FLT3 inhibitor and Hypomethylating agent for the treatment of the acute myeloid leukemia
WO2020171649A1
Pharmaceutical combination comprising flt3 inhibitor and iap antagonist for treatment of acute myeloid leukemia
KR20200102948A
A pharmaceutical combination comprising FLT3 inhibitor and IAP antagonist for the treatment of the acute myeloid leukemia
KR20200096157A
Imidazopyridine derivative compound and use thereof
WO2020159285A1
Imidazopyridine derivative compounds and use of same
KR20200009101A
Pharmaceutical composition comprising amlodipine, losartan and rosuvastatin for prevention and treatment of cardiovascular diseases accompanied by diabetes and formulated combination including the same
KR20200078414A
A pharmaceutical composition comprising insulin and glucagon
